Stockscreener 앱 받기
77.91
0.68%
0.16
전일 마감가:
$77.75
열려 있는:
$78.05
하루 거래량:
1.54M
Relative Volume:
0.50
시가총액:
$15.26B
수익:
$579.96M
순이익/손실:
$-729.89M
주가수익비율:
-20.80
EPS:
-3.7459
순현금흐름:
$-452.02M
1주 성능:
+5.10%
1개월 성능:
+15.78%
6개월 성능:
+5.40%
1년 성능:
+79.95%
1일 변동 폭
$76.19
$78.90
1주일 범위
$73.56
$79.25
52주 변동 폭
$42.09
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
77.94 | 15.23B | 579.96M | -729.89M | -452.02M | -3.7459 |
VRTX
Vertex Pharmaceuticals Inc
|
521.98 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.86 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.90 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.14 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.47 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-09 | 개시 | RBC Capital Mkts | Outperform |
| 2026-03-10 | 개시 | William Blair | Outperform |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-06 | 개시 | Morgan Stanley | Overweight |
| 2025-12-11 | 개시 | Bernstein | Outperform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-14 | 개시 | Jefferies | Buy |
| 2025-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-03 | 개시 | Oppenheimer | Perform |
| 2024-09-04 | 개시 | Piper Sandler | Overweight |
| 2024-03-21 | 재개 | Raymond James | Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-07 | 개시 | Citigroup | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-19 | 개시 | Evercore ISI | Outperform |
| 2023-02-06 | 개시 | Cowen | Outperform |
| 2021-12-27 | 재확인 | Mizuho | Buy |
| 2021-12-27 | 재확인 | SVB Leerink | Outperform |
| 2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-03-22 | 재확인 | Goldman | Buy |
| 2021-02-22 | 재개 | JP Morgan | Overweight |
| 2021-02-09 | 재개 | Goldman | Buy |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Neutral |
| 2020-05-19 | 개시 | BTIG Research | Buy |
| 2020-04-13 | 개시 | H.C. Wainwright | Buy |
| 2020-02-19 | 개시 | Mizuho | Buy |
| 2019-07-26 | 개시 | Raymond James | Outperform |
| 2019-07-22 | 개시 | BMO Capital Markets | Outperform |
| 2019-07-22 | 개시 | Goldman | Buy |
| 2019-07-22 | 개시 | JP Morgan | Overweight |
| 2019-07-22 | 개시 | Jefferies | Buy |
| 2019-07-22 | 개시 | Piper Jaffray | Overweight |
| 2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
BridgeBio Pharma’s SWOT analysis: stock gains momentum on pipeline strength - Investing.com
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.
BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update) - MSN
Jefferies Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100 - Moomoo
BridgeBio Pharma reportedly in talks for $1B preferred equity from KKR, Sixth Street - MSN
Price to book forward of BridgeBio Pharma, Inc. – NASDAQ:BBIO - TradingView
If You Invested $1,000 in Bridgebio Pharma (BBIO) - Stock Titan
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BridgeBio Pharma Raises $933.9 Million Via 7% Convertible Preferred From Sixth Street, HCRx - TradingView
BridgeBio (Nasdaq: BBIO) secures $933.9M in senior convertible preferred equity - Stock Titan
BridgeBio reports kidney function data for acoramidis in ATTR-CM - Investing.com
BridgeBio reports kidney function data for acoramidis in ATTR-CM By Investing.com - Investing.com South Africa
BridgeBio Pharma Announces New Circulation: Heart Failure Analyses Showing Kidney-Protective Effects of Acoramidis in ATTR-CM - Quiver Quantitative
BridgeBio says acoramidis showed kidney protection in ATTR-CM study - Stock Titan
Latham & Watkins Advises BridgeBio on Up to US$1 Billion Preferred Equity Investment, One of the Largest Preferred Investments for Public Biotechs Ever and the Largest in 2026 - Legal Desire Media and Insights
BridgeBio lands $1 billion, mostly from S.F.'s Sixth Street, with three late-stage drugs in hand - The Business Journals
BridgeBio Pharma Announces $1 Billion Convertible Preferred Equity Deal - Moomoo
BridgeBio raises $1 billion in preferred equity - The Pharma Letter
BridgeBio secures up to $1B in preferred equity - MSN
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches - Sixth Street
BridgeBio secures $1 billion in convertible preferred equity By Investing.com - Investing.com South Africa
BridgeBio Pharma | SCHEDULE 13D/A: Others - Moomoo
BridgeBio secures $1 billion in convertible preferred equity - Investing.com
BridgeBio gets $1B from Sixth Street, HCRx for three launches - Stock Titan
BridgeBio gets funding for drug launch; United buys into cell therapy - Yahoo Finance
Global private equity giants continue to increase investments in the innovative pharmaceuticals sector, with firms including KKR injecting $1 billion into BridgeBio. - Moomoo
Market Chatter: KKR, Sixth Street to Invest $1 Billion in BridgeBio Preferred Equity - 富途牛牛
Sixth Street, KKR Provide BridgeBio $1 Billion Preferred Equity - Bloomberg.com
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential? - Yahoo Finance
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) dropped from Russell 2000 Index - marketscreener.com
BridgeBio: 3 New Drug Approvals In Sight Outweigh Attruby Issues, Still Bullish (BBIO) - Seeking Alpha
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Value Benchmark - marketscreener.com
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Growth Benchmark - marketscreener.com
Sector Update: Healthcare - Moomoo
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) dropped from Russell 2000 Growth Benchmark - marketscreener.com
BridgeBio Pharma Meets Primary Endpoint For Achondroplasia Drug in Phase 3 Trial - Moomoo
BridgeBio Pharma, Inc. (BBIO): Investor Outlook Highlights 45.61% Potential Upside Amid Robust Pipeline - DirectorsTalk Interviews
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell 1000 Value Benchmark - marketscreener.com
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell 1000 Growth Benchmark - marketscreener.com
BridgeBio (BBIO) Reports Positive Phase 3 Results for Infigratin - GuruFocus
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) added to Russell Midcap Index - marketscreener.com
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia - The Manila Times
BridgeBio Pharma Announces NEJM Publication and ICCBH Presentation of Positive Phase 3 PROPEL 3 Data for Oral Infigratinib in Achondroplasia - Quiver Quantitative
BridgeBio's achondroplasia drug posts NEJM Phase 3 data - Stock Titan
BridgeBio Pharma, Inc.(NasdaqGS: BBIO) dropped from Russell 2000 Dynamic Index - marketscreener.com
BridgeBio Pharma, Inc. Actuals & Estimates (NASDAQ:BBIO) - TradingView
BridgeBio shareholders approve board changes and equity plan - The Globe and Mail
BBIO Forecast — Price Target — Prediction for 2027 - TradingView
BridgeBio Pharma Adopts Third Amended 2021 Stock Option and Incentive Plan Following Shareholder Approval - Minichart
BridgeBio Pharma (NASDAQ: BBIO) shareholders approve directors and add 2M plan shares - Stock Titan
BridgeBio Pharma, Inc. Announces the Resignation of Randal W. Scott as Class I Director, Effective as of June 22, 2026 - marketscreener.com
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bridgebio Pharma Inc 주식 (BBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cook Jennifer E. | Director |
Jun 24 '26 |
Sale |
70.00 |
37,167 |
2,601,690 |
8,383 |
| Cook Jennifer E. | Director |
Jun 23 '26 |
Sale |
68.57 |
2,196 |
150,580 |
8,383 |
| Valantine Hannah | Director |
Jun 22 '26 |
Option Exercise |
41.73 |
2,808 |
117,178 |
14,263 |
| Valantine Hannah | Director |
Jun 22 '26 |
Sale |
68.00 |
2,808 |
190,944 |
11,455 |
| Valantine Hannah | Director |
Jun 23 '26 |
Sale |
68.57 |
2,196 |
150,580 |
9,259 |
1.21%
3.14%
자본화:
|
볼륨(24시간):